Rockland Trust Co. increased its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) by 3,699.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,404 shares of the medical instruments supplier's stock after purchasing an additional 47,130 shares during the quarter. Rockland Trust Co.'s holdings in West Pharmaceutical Services were worth $14,636,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also recently added to or reduced their stakes in WST. Allworth Financial LP lifted its stake in shares of West Pharmaceutical Services by 140.0% in the 1st quarter. Allworth Financial LP now owns 72 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 42 shares in the last quarter. Addison Advisors LLC lifted its stake in shares of West Pharmaceutical Services by 221.7% in the 1st quarter. Addison Advisors LLC now owns 74 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 51 shares in the last quarter. Artemis Wealth Advisors LLC acquired a new position in shares of West Pharmaceutical Services in the 1st quarter valued at about $35,000. American National Bank lifted its stake in shares of West Pharmaceutical Services by 55.6% in the 1st quarter. American National Bank now owns 98 shares of the medical instruments supplier's stock valued at $40,000 after purchasing an additional 35 shares in the last quarter. Finally, Dividend Assets Capital LLC acquired a new position in shares of West Pharmaceutical Services in the 4th quarter valued at about $51,000. 91.98% of the stock is owned by institutional investors and hedge funds.
Get
West Pharmaceutical Services alerts:
Insiders Place Their Bets
In other West Pharmaceutical Services news, insider Silji Abraham sold 5,374 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $343.93, for a total transaction of $1,848,279.82. Following the sale, the insider now directly owns 3,201 shares in the company, valued at approximately $1,100,919.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.60% of the stock is owned by company insiders.
West Pharmaceutical Services Trading Down 2.1 %
Shares of NYSE WST traded down $5.77 during midday trading on Tuesday, hitting $264.16. The stock had a trading volume of 11,154 shares, compared to its average volume of 358,028. The company has a market capitalization of $19.56 billion, a price-to-earnings ratio of 29.33, a PEG ratio of 1.08 and a beta of 1.18. West Pharmaceutical Services, Inc. has a 1-year low of $261.31 and a 1-year high of $475.00. The company has a quick ratio of 2.41, a current ratio of 3.13 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average price of $312.53 and a 200 day moving average price of $330.25.
West Pharmaceutical Services (NYSE:WST – Get Rating) last released its quarterly earnings results on Thursday, July 28th. The medical instruments supplier reported $2.47 EPS for the quarter, topping the consensus estimate of $2.19 by $0.28. The firm had revenue of $771.30 million for the quarter, compared to analyst estimates of $754.25 million. West Pharmaceutical Services had a return on equity of 29.08% and a net margin of 23.41%. West Pharmaceutical Services's revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.46 EPS. On average, analysts predict that West Pharmaceutical Services, Inc. will post 9.09 earnings per share for the current year.
West Pharmaceutical Services Profile
(Get Rating)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Read More
- Get a free copy of the StockNews.com research report on West Pharmaceutical Services (WST)
- Has AMD stock stock fallen too far?
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
